Rethink field services: Three myths keeping access barriers in front of your product
Pharma in the field: Sales reps vs. reimbursement and access specialists
The Future of Payer Engagement: How Pharma Can Break Through
The Value of Virtual: How Remote Workshops Can Keep Market Access Efforts Moving
Regulatory and Market Access Impact in Europe of the Recent Medical Software Makers Guidance
Emerging Gene Therapies for Hemophilia in the United States—Value Drivers in a Crystal Ball
Webinar: Navigating Pre-approval Information Exchange (PIE) and the AMCP Format for Formulary Submissions, Version 4.1
This webinar will provide an overview of pre-approval information exchange (PIE), review the changes and discuss the implications of the recently released AMCP Format v4.1, and provide manufacturer considerations and recommendations for PIE and the pre-approval dossier.
Biosimilars: Launch Insights From the Field
How are biosimilar manufacturers approaching patients, providers and payers? What can they do to differentiate? Xcenda shares insight from our field programs.
Review of HTA Frameworks and Decisions for Next-Generation Sequencing in Precision Oncology
Tumor-Agnostic Therapy Assessment: Following Regulatory Approval, What Challenges Exist for HTAs?
How Digital Innovation Drives Improved Market Access Strategies
In this digital age, how can pharmaceutical manufacturers leverage innovative tools to prove their product's value proposition and overcome market access challenges?
Xcenda Celebrates 25th Anniversary by Launching New Value & Market Access Solutions
Upending the Medicare Part B Program: The International Pricing Index (IPI) Proposed Model
The Evolving Healthcare Landscape and the Impact on Patient Access and Affordability
Managing the Growing Expansion of Copay Accumulators
Responding to Stakeholder Input: Finding the Patient Voice in ICER's Value Assessments
Medicare Physician-Administered Drugs: Do Providers Choose Treatment Based on Payment Amount?
Therapeutic Spotlight: Assessments of Emerging Therapies for Tardive Dyskinesia
Taiwan: 10 Years of the Center for Drug Evaluation (CDE) Health Technology Assessment Division
Emerging Trends in PBM Restrictions on Commercial Copay Assistance
How to Navigate Cell and Gene Therapy Reimbursement: Part One
An executive Q&A on challenges and opportunities related to reimbursement, coding and coverage for cell and gene therapies.
How to Navigate Cell and Gene Therapy Reimbursement: Part Two
An executive Q&A on the role of data and the future of innovative reimbursement modeling for cell and gene therapies.
Rethink: Payer Strategies for Commercializing Cell and Gene Therapies
HTAQ Summer 2017 Duchenne Muscular Dystrophy New and Revitalized Drugs Bring Hope to Patients
Payer Perceptions and Utilization of ICER Value Assessment Framework
Xcenda examines the impact of the ICER value assessment framework on payer perceptions.